Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the month of May 2004. The registrant is a foreign private issuer based in South Melbourne, Victoria, Australia. The filing primarily serves to disclose a new issue of securities and an application for quotation on the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
The filing details a specific capital event rather than providing a full financial statement. Key metrics include:
- Securities Issued: 100,000 Ordinary Shares.
- Issue Price: $0.70 per share.
- Purpose of Issue: Exercise of options (specifically class PBTAS).
- Total Quoted Securities: 74,259,380 Ordinary Shares (PBT) on the ASX.
- Outstanding Options: The company holds various option classes, including 20,000,000 options exercisable at $0.50 (PBTAK) and 1,347,167 employee/consultant options (PBTAO).
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios.
Material Changes
The primary material change reported is the increase in the number of ordinary shares outstanding due to the exercise of 100,000 options on April 15, 2004. These new shares rank pari passu with existing ordinary shares. No other material changes to operations or financial position are detailed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond standard regulatory warranties. The company warrants that the issue complies with the law, is not for an illegal purpose, and that no person has a right to return the securities under specific sections of the Corporations Act. The dividend policy remains unchanged.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issue (74,259,380) against subsequent filings to confirm dilution impact.
- Confirm the exercise price ($0.70) relative to the prevailing market price at the time of exercise to assess the value of the option grant.
- Review the status of the 20,000,000 options (PBTAK) exercisable at $0.50, as these represent significant potential dilution.
- Check for any subsequent financial reports (Form 20-F) to obtain actual revenue and cash flow data, as this 6-K does not contain them.